Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Good Girl Rx vs WellMedr

Good Girl Rx
Graded #446

Lower grade

vs+6.3
WellMedr
Graded #218

Higher grade

The verdict

WellMedr takes it — 63.2/100 to 56.9/100.

WellMedr grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Sells an eight-product low-dose line alongside brand Ozempic and Zepbound — and prices the tirzepatide the same at every dose.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueWellMedr +30
28
58
Dose & formulationGood Girl Rx +14
88
74
Clinical oversightWellMedr +16
55
71
Labs & monitoringWellMedr +6
52
58
FulfillmentGood Girl Rx +23
85
62
Contract termsWellMedr +3
41
44
Good Girl Rx · left barWellMedr · right bar

The numbers

MetricGood Girl RxWellMedr
WeighScore56.9/10063.2/100
GradeCC
Scorecard rank#446#218
Semaglutide$79/mo (microdose tier, 12-month plan, compounded)$59/mo on a 12-month plan
Tirzepatide$139/mo (microdose tier, 12-month plan, compounded)$99/mo on a 12-month plan
CoverageAll 50 statesCoverage not published
Brand-name accessYesYes
Oral / sublingualYesYes
Good Girl Rx

Graded #446 · C

FDAWarning letter issued to Good Girl LLC dba GoodGirlRX in February 2026. See the FDA warning-letter database.

Strengths

  • LegitScript certified
  • Multiple formats — injectable, microdose, and ODT pills — for both semaglutide and tirzepatide
  • Dispensed by licensed 503A or 503B pharmacies
  • Limited brand-name options available (Ozempic, Wegovy, Zepbound, Mounjaro)
  • Named legal entity with a Nashville address

Where it loses points

  • The advertised rates require twelve months paid up front; billed month to month the same products are $184 and $244, roughly 2.3 times as much
  • Every plan is prepaid — the discount exists only on the 3-, 6- and 12-month terms
  • The priced products are microdoses, not labeled therapeutic doses; the standard compounded semaglutide is $134/mo and also needs a year up front
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
  • FDA issued Good Girl LLC dba GoodGirlRX a warning letter in February 2026; the letter is public in FDA's warning-letter database
WellMedr

Graded #218 · C

Strengths

  • Eight named microdose products across oral and injectable routes, each with its formulation published — a real low-dose line, not a smaller amount of a standard plan
  • States its dose basis outright on the tirzepatide plan: "Same price regardless of dosage"
  • Publishes what a "month" contains — both plans say "shipped every 4 weeks" on the plan card itself
  • Names the treating clinical group in its telehealth consent: OpenLoop Health, Inc. and its state professional corporations
  • Names both halves of the supply chain: OpenLoop Health, Inc. as the medical group and "Mycelium Pharmacy — our U.S.-licensed fulfillment pharmacy" as the dispenser — most compounded sellers name neither
  • Puts the compounding caveat on the pricing page, not in a footer: compounded medications are "regulated by state Boards of Pharmacy, but are not evaluated by the FDA for safety or efficacy", with explicit thyroid C-cell tumor and MTC warnings
  • Offers FDA-approved brand product — Ozempic from $1,399, Zepbound from $1,599 — for anyone who decides against compounded

Where it loses points

  • The microdose page headlines "ZERO Side Effects", subheaded "Zero side effct for 70%+ of members" (their typo) — an unqualified claim no evidence supports, on a page that carries no safety notice at all — the thyroid C-cell tumor warning is on the pricing page, not this one
  • ITS FAQ SAYS THE MEDICATIONS ARE FDA APPROVED. Asked "Are these medications FDA approved?", the page answers "Yes. We only work with U.S. licensed pharmacies that dispense FDA-approved medications" — while the footer of that same page says they are "not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality". A buyer asking the one regulatory question that matters is told the opposite of the truth
  • TWO DIFFERENT BILLING CYCLES ARE PUBLISHED. The plan cards say "shipped every 4 weeks" — 13 charges a year — while the refund policy says the subscription "will automatically renew every 21 days", which is about 17. Which one your card sees is not knowable from the site
  • The advertised $59 is a twelve-month rate — the banner reads "Lock In $200 OFF Every Month, or $59/mo on 12/month Plans — For Life". It names only that figure; the $99 tirzepatide card carries no such condition and says "Cancel or change anytime". Yet no standing month-to-month rate is published for either molecule
  • A "month" is four weeks on both plans, so a year is 13 charges rather than 12 — about 8.6% more than the monthly label implies
  • Six of the eight microdose products publish no price at all; the two that do both show $199/month regardless of formulation
  • The semaglutide plan makes no statement about dose basis in either direction, so whether a low dose costs less there is simply unknown
  • Two discounts stack — "$200 OFF Every Month" and a separate "$150 off for Life" — and neither reverses into a standing rate
  • The results carousel is disclosed as "Inspired by real patient success stories in similar Telehealth programs", so those figures are not WellMedr patients
  • The top bar advertises "FDA-regulated pharmacies" — a claim about the pharmacy, not the drug
  • The pharmacy is named only in the privacy policy — not on the pricing page, the microdose page or anywhere a buyer would look for it

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 544 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard